1. Home
  2. ALNY vs CUK Comparison

ALNY vs CUK Comparison

Compare ALNY & CUK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$295.50

Market Cap

39.0B

Sector

Health Care

ML Signal

HOLD

Logo Carnival Plc ADS ADS

CUK

Carnival Plc ADS ADS

HOLD

Current Price

$27.42

Market Cap

38.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALNY
CUK
Founded
2002
1972
Country
United States
United States
Employees
115
117000
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
39.0B
38.7B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
ALNY
CUK
Price
$295.50
$27.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
28
22
Target Price
$471.00
$33.99
AVG Volume (30 Days)
973.6K
4.0M
Earning Date
04-30-2026
03-27-2026
Dividend Yield
N/A
0.59%
EPS Growth
206.88
N/A
EPS
2.33
N/A
Revenue
$1,037,418,000.00
N/A
Revenue This Year
$52.67
$7.64
Revenue Next Year
$31.48
$3.42
P/E Ratio
$127.61
$16.36
Revenue Growth
22.88
N/A
52 Week Low
$284.28
$20.05
52 Week High
$495.55
$33.72

Technical Indicators

Market Signals
Indicator
ALNY
CUK
Relative Strength Index (RSI) 45.21 53.55
Support Level $285.64 $25.81
Resistance Level $331.27 $27.85
Average True Range (ATR) 8.85 0.95
MACD 1.35 -0.07
Stochastic Oscillator 49.98 46.41

Price Performance

Historical Comparison
ALNY
CUK

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

About CUK Carnival Plc ADS ADS

Carnival is the largest global cruise company, with nearly 100 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 14 million guests in 2025.

Share on Social Networks: